The first affiliated hospital of Ningbo university

Ningbo, Zhejiang 315010

12 studies enrolling now · 20 studies all time

What they study most

Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Advanced/Metastatic Urothelial Cancer, Atherosclerotic Cardiovascular Disease, Cancer of the Prostate, Carcinoma, Renal Cell, Carcinoma, Renal Cell Metastasis, Carcinoma, Renal Cell, Advanced, Chronic Kidney Disease, Chronic Lymphocytic Leukemia, Clear Cell Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma

Studies at this site

• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Recruiting now
• A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy — Recruiting now
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC) — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Recruiting now
• A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) — Recruiting now
• Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
• A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma — Recruiting now
• An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Enrolling by invitation
• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy — Running, not enrolling
• Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Running, not enrolling
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer — Stopped early
• A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Running, not enrolling
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease — Withdrawn before enrolling